BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15820075)

  • 1. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
    Cai X; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):39-43. PubMed ID: 22490854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients].
    Young Kim W; Maeda K; Noda E; Fukunaga S; Inoue T; Kaizaki R; Shinto O; Wada K; Nakano T; Hirakawa K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1833-6. PubMed ID: 18030018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
    Ishida H; Shirakawa K; Ohsawa T; Sobajima J; Hayashi Y; Nakada H; Yokoyama M; Hashimoto D
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1929-34. PubMed ID: 16282729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.
    Reerink O; Mulder NH; Szabo BG; Hospers GA
    Anticancer Res; 2004; 24(3b):1969-71. PubMed ID: 15274386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose leucovorin, fluorouracil and oral dipyridamole in the treatment of advanced colorectal cancer.
    Fountzilas G; Zisiadis A; Kosmidis P; Basdanis G; Makrantonakis P; Paspatis A; Tsavdaridis D; Tsavaris N; Aletras O; Tourkantonis A
    Anticancer Res; 1991; 11(2):865-8. PubMed ID: 2064344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
    Inoue T; Hibi K; Nakayama G; Komatsu Y; Fukuoka T; Kodera Y; Ito K; Akiyama S; Nakao A
    J Gastroenterol; 2005 Feb; 40(2):143-7. PubMed ID: 15770397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.